Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,548,170
  • Shares Outstanding, K 103,413
  • Annual Sales, $ 494,370 K
  • Annual Income, $ 19,810 K
  • 60-Month Beta 1.08
  • Price/Sales 46.50
  • Price/Cash Flow 702.42
  • Price/Book 61.78
Trade NVCR with:

Options Overview

Details
  • Implied Volatility 46.07%
  • Historical Volatility 26.56%
  • IV Percentile 14%
  • IV Rank 17.06%
  • IV High 82.73% on 02/24/21
  • IV Low 38.54% on 08/27/20
  • Put/Call Vol Ratio 0.20
  • Today's Volume 1,077
  • Volume Avg (30-Day) 973
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 45,181
  • Open Int (30-Day) 44,121

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.02
  • Number of Estimates 6
  • High Estimate 0.05
  • Low Estimate -0.01
  • Prior Year 0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
172.85 +26.14%
on 05/19/21
228.10 -4.41%
on 06/18/21
+37.75 (+20.94%)
since 05/18/21
3-Month
119.60 +82.31%
on 03/26/21
228.10 -4.41%
on 06/18/21
+80.28 (+58.28%)
since 03/18/21
52-Week
55.40 +293.57%
on 07/14/20
228.10 -4.41%
on 06/18/21
+155.53 (+248.81%)
since 06/18/20

Most Recent Stories

More News
Novocure Initiates Usability Study for Flexible Torso Array

Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four clinical sites...

NVCR : 218.04 (-1.92%)
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile(R) Therapy in Recurrent Glioblastoma

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical...

NVCR : 218.04 (-1.92%)
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal...

NVCR : 218.04 (-1.92%)
Late Selloff Sends Stocks Lower for Second Day

Late Selloff Sends Stocks Lower for Second Day

STNE : 68.29 (+2.99%)
NVCR : 218.04 (-1.92%)
CHGG : 79.99 (+1.87%)
FLO : 23.73 (-2.35%)
RUTH : 22.10 (-2.77%)
SAVA : 79.65 (+1.34%)
ARMK : 36.08 (-3.58%)
HTHT : 54.65 (+2.28%)
PTON : 109.12 (+0.28%)
PLBY : 36.54 (+1.22%)
FOUR : 98.48 (+0.21%)
RUN : 52.71 (+1.05%)
TMUS : 144.70 (-1.19%)
ALTO : 5.59 (-6.68%)
DDS : 154.02 (-2.93%)
WMT : 135.17 (-1.85%)
HD : 302.61 (-0.17%)
M : 17.72 (-2.26%)
CSCO : 52.07 (-2.00%)
LOW : 186.88 (+0.02%)
TGT : 230.53 (-0.30%)
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for...

NVCR : 218.04 (-1.92%)
Stocks Drop 2% as Inflation Jumps

Stocks Drop 2% as Inflation Jumps

UCTT : 49.88 (-8.71%)
BIGC : 63.46 (+4.81%)
STNE : 68.29 (+2.99%)
TWTR : 60.85 (+0.23%)
NVCR : 218.04 (-1.92%)
HTHT : 54.65 (+2.28%)
CHGG : 79.99 (+1.87%)
BABA : 212.30 (+0.33%)
DIS : 172.42 (-1.28%)
GOOG : 2,511.35 (-0.64%)
AAPL : 130.46 (-1.01%)
AMZN : 3,486.90 (-0.07%)
NFLX : 500.77 (+0.49%)
MSFT : 259.43 (-0.56%)
NVE Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / NVE Corp. (NASDAQ:NVEC) will be discussing their earnings results in their 2021 Fourth Quarter Earnings call to be held on May 5, 2021 at 5:00 PM Eastern Time....

NVCR : 218.04 (-1.92%)
NVEC : 67.77 (-2.71%)
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

--Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size

NVCR : 218.04 (-1.92%)
NovoCure Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 29, 2021 / NovoCure Ltd. (NASDAQ:NVCR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 8:00 AM Eastern...

NVCR : 218.04 (-1.92%)
Why NovoCure (NVCR) Might Surprise This Earnings Season

NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NVCR : 218.04 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 235.11
2nd Resistance Point 231.60
1st Resistance Point 224.82
Last Price 218.04
1st Support Level 214.53
2nd Support Level 211.03
3rd Support Level 204.25

See More

52-Week High 228.10
Last Price 218.04
Fibonacci 61.8% 162.13
Fibonacci 50% 141.75
Fibonacci 38.2% 121.37
52-Week Low 55.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar